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A Phase III Randomized Trial of Gemcitabine–Oxaliplatin
versus Carboplatin–Paclitaxel as First-Line Therapy in
Patients with Advanced Non-small Cell Lung Cancer
Charles H. Weissman, MD,* Craig H. Reynolds, MD,* Marcus A. Neubauer, MD,*
Sharon Pritchard, RN,* Svetlana Kobina, MD, PhD,† and Lina Asmar, PhD*
Purpose: This phase III study compared the efficacy and tolerability
of gemcitabine and oxaliplatin (GEMOX) with paclitaxel and car-
boplatin (PCb) in chemotherapy-naive patients with stage IIIB/IV
non-small cell lung cancer.
Patients and Methods: Patients aged 18 years or older were
randomized to PCb (paclitaxel 225 mg/m2 followed by carboplatin
area under the curve  6 on day 1 every 3 weeks) or GEMOX
(gemcitabine 1,000 mg/m2 on days 1 and 8 followed by oxaliplatin
130 mg/m2 on day 1 every 3 weeks) for up to six cycles. The
primary end point was progression-free survival (PFS), with tumor
response rate, overall survival (OS), and quality of life as secondary
end points.
Results: The study was terminated after 383 patients had been
randomized (371 received treatment) as the incidence of adverse
events had exceeded the protocol-specified safety threshold (20%
in either arm). No formal statistical comparisons were conducted.
Median PFS was 4.44 months and 4.67 months in the GEMOX and
PCb groups, respectively. Objective response rates (complete or
partial) were 15.2% and 22.4% in the GEMOX and PCb arms,
respectively. Median OS was 9.90 months (GEMOX) and 9.24
months (PCb); post hoc analyses showed median OS in patients
aged 70 years or older to be similar to those younger than 70 years.
PFS was similar in both groups of patients with adenocarcinoma
histology, although OS favored the GEMOX group. Quality of life
was improved from baseline in both groups. Toxicity profiles were
comparable between the groups.
Conclusion: PFS, OS, and objective response rates with GEMOX
were similar to PCb. Nevertheless, toxicities limit the adoption of
this regimen for routine use in advanced non-small cell lung cancer.
Key Words: Chemotherapy, Cisplatin, First-line, Lung cancer,
Metastatic, Oxaliplatin, Phase III.
(J Thorac Oncol. 2011;6: 358–364)
Platinum-containing combinations are standard therapy foradvanced non-small cell lung cancer (NSCLC), achieving
significant reductions in overall mortality and disease pro-
gression compared with nonplatinum regimens.1 The most
commonly used regimen for the treatment of advanced
NSCLC in the United States is the combination of paclitaxel
and carboplatin (PCb), the efficacy of which has been estab-
lished in randomized phase III studies.2–6 On the basis of
efficacy and toxicity results from the Eastern Cooperative
Oncology Group (ECOG) study 1594 comparing four che-
motherapy regimens in patients with stage IIIb or IV NSCLC,
PCb was recommended by the authors as the reference
regimen for future trials.5
Oxaliplatin is a platinum compound with a similar
mechanism of action to cisplatin. In vitro data suggested that
the mechanisms of action of oxaliplatin and gemcitabine may
be synergistic.7 In a phase II study in patients with metastatic
NSCLC, the combination of gemcitabine and oxaliplatin
(GEMOX) demonstrated a favorable side-effect profile and
an overall response rate (RR) of 31%, with a median overall
survival (OS) of 11.3 months.8 A number of GEMOX dosing
regimens have been studied in NSCLC. From a phase I/II trial
conducted by a consortium of centers in the United States, the
recommended dose regimen was gemcitabine 1000 mg/m2 on
days 1 and 8 and oxaliplatin 130 mg/m2 on day 1, every 3
weeks.9 This schedule was chosen for this study.
This study was conducted to determine the relative
efficacy, safety, and clinical benefit of GEMOX compared
with PCb as first-line therapy for patients with stage IIIB/IV
NSCLC. The primary end point was progression-free survival
(PFS); secondary end points were tumor RR, time to treat-
ment failure (TTF), OS, safety, and quality of life (QoL).
METHODS
Patient Eligibility
Enrolled patients were aged 18 years or older with
histologically confirmed, newly diagnosed, untreated, stage
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IIIB or IV NSCLC, 1 measurable (unidimensional) lesion
with diameter 20 mm using conventional computed tomog-
raphy (CT) or magnetic resonance imaging, or 10 mm
using spiral CT, and an ECOG performance status of 0 or 1.
Other inclusion criteria included no history of an acute
cardiac or central nervous system event within 6 months of
study entry; no current congestive heart failure or unstable
coronary artery disease; adequate hematologic, hepatic, and
renal function tests; negative pregnancy test in women; and
no peripheral neuropathy of grade more than 1. Exclusion
criteria included symptomatic brain metastases; history of
hypersensitivity to any of the four study drugs; receipt of
concurrent immunotherapy; serious uncontrolled medical
or psychiatric illness; and history of other malignancy
within the last 5 years (except for squamous or basal cell
carcinoma of the skin, carcinoma in situ of the cervix, or
superficial transitional cell carcinoma of the bladder). The
study protocol was approved by the institutional review
boards before patient enrollment. All patients provided
written informed consent.
Treatment Plan
Patients were randomly assigned to receive GEMOX
(gemcitabine 1000 mg/m2 over 30 minutes on days 1 and 8
followed by oxaliplatin 130 mg/m2 over 2 hours on day 1,
every 3 weeks) or PCb (paclitaxel 225 mg/m2 over 3 hours on
day 1 followed by carboplatin area under the curve  6 over
30–60 minutes on day 1, every 3 weeks). Treatment was
planned for a maximum of six cycles unless discontinued
because of disease progression, unacceptable toxicity, physi-
cian or patient decision, pregnancy, requirement for palliative
radiotherapy, or death. Patients treated with oxaliplatin could
receive 5-HT3 receptor antagonists, with or without dexa-
methasone, whereas patients treated with paclitaxel could
receive dexamethasone and H1 and H2 receptor antagonists
before infusion. Supportive care, including bisphosphonates
and prophylaxis for neurotoxicity, was also permitted.
A single-dose reduction was permitted for each drug
based on worst toxicity for any organ system during the
previous cycle. Further dose reductions required discontinu-
ation. For nonhematologic toxicity of grade 2, the drug
doses of both regimens were delayed until toxicity had
declined to grade 1. For grade 3 nonhematologic toxicity,
all study drugs were given at their reduced doses (gemcitab-
ine 750 mg/m2; oxaliplatin 100 mg/m2; paclitaxel 175 mg/
m2; and carboplatin area under the curve  5). Patients
experiencing grade 4 nonhematologic toxicity were with-
drawn from the study. In the case of persistent grade 2
neurologic toxicity or grade 3 toxicity lasting for more than 7
days, dose reductions were introduced for oxaliplatin, pacli-
taxel, and carboplatin. In the event of grade 4 neurologic
toxicity, or grade 3/4 acute hypersensitivity or anaphylactic
reactions, the patient was withdrawn. In the case of febrile
neutropenia on day 1, all study drugs were given at their
reduced doses. On the first occurrence of thrombocytopenia,
only gemcitabine and carboplatin doses were reduced. On the
second occurrence of thrombocytopenia, only oxaliplatin and
paclitaxel doses were reduced. When the absolute neutrophil
count was in the range 500 to 999 cells/L, gemcitabine was
delayed until absolute neutrophil count 1000 cells/L and
was then given at its reduced dose.
Assessment of Efficacy and Safety
Tumor response was evaluated after cycles 2 and 4
using RECIST criteria.10 Tumor assessment was performed
by CT scan (RECIST) after cycles 2 and 4, and after cycle 6
for patients who had a response at cycle 4. To be assigned the
status of a partial response (PR) or complete response (CR),
tumor measurements had to be confirmed 4 weeks after
criteria for the response were first met. Toxicities were
graded before each treatment cycle according to National
Cancer Institute Common Toxicity Criteria for adverse events
(AEs) (Version 3.0).
A QoL Functional Assessment of Cancer Therapy-
Lung questionnaire was completed after every cycle. This
questionnaire is divided into physical, social/family, emo-
tional, and functional well-being subdomains and includes a
lung cancer subscale (symptoms, cognitive function, and
regret of smoking). The Trial Outcome Index (TOI) was
calculated as the sum of the physical, functional, and lung
cancer subscales. Reductions in TOI indicate improvements
in QoL.
Statistical Analysis
Assuming a recruitment duration of 22 months and that
the last accrued subject would be followed for 8 months, a
hazard ratio (HR) of 1.3, and median PFS for subjects on PCb
of 3.1 months, a sample size of 480 patients (240 in each
group) was sufficient to provide 80% power to detect the
difference between two treatments using a two-sided test with
a type I error of 5%.
PFS was defined as time from date of randomization to
date of first observation of progression or death due to any
cause. TTF was defined as time from randomization to time
the patient was removed from the study for any of the
following events: withdrawal due to AEs; progressive disease
(PD) or insufficient therapeutic response; failure to return;
treatment refusal/lack of cooperation/withdrawal of consent;
new treatment started; or death.
OS and PFS were estimated using the Kaplan-Meier
method. Nevertheless, no formal statistical analyses were
conducted to compare the two treatment groups with respect
to the primary end point because the early termination did not
allow for sufficient enrollment to adequately power the study.
In post hoc analyses, OS and PFS were assessed in
patients according to age (70 years versus 70 years) and
tumor histology (adenocarcinoma versus squamous).
The intent-to-treat (ITT) population comprised all sub-
jects who were randomized, regardless of whether they re-
ceived any study drug or therapy different from that to which
they were randomized. The safety population consisted of all
subjects who received 1 dose of any of the study drugs.
Two interim analyses were planned: after 154 and 308
subjects had documented PD, respectively. If, at the time of
interim analysis, 20% of patients in either treatment group
had discontinued study therapy due to unacceptable toxicity,
the study would be terminated.
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RESULTS
After the results of the first interim analysis, enrollment
was stopped after 383 subjects (371 were treated) at the cutoff
date because the number of patients with AEs had exceeded
the protocol-specified safety threshold for study continuance.
The study was terminated early following a recommendation
by the Independent Data Monitoring Committee. Patients
enrolled in the study up to this date were allowed to continue
study treatment and follow-up. Between March 4, 2004, and
April 15, 2005, 383 patients were enrolled, of whom 191 and
192 were randomized to the GEMOX and PCb arms, respec-
tively (ITT population). Of these, 371 patients received treat-
ment and had full safety data available. Two-year survival
follow-up was completed on March 31, 2007.
Overall, 130 of 383 patients (33.9%) completed the six
cycles of treatment (GEMOX, 57/191 [29.8%] and PCb,
73/192 [38.0%]) and 33 of 383 (8.6%) went on to complete
2 years of follow-up (GEMOX, 20/191 [10.5%] and PCb,
13/192 [6.8%]). Patients in both treatment groups received a
median of four (range: 1–6) cycles of chemotherapy. The
median duration of treatment was 10.1 weeks in both treatment
groups (range: GEMOX, 0–20 and PCb, 0–18). Patient dispo-
sition is summarized in Figure 1. Patient demographics and
clinical characteristics are presented in Table 1. The treat-
ment arms were balanced for age, sex, disease stage, and
histologic grade. More than 80% of patients had stage IV
disease in both arms. The most common histologic subtype
was adenocarcinoma (GEMOX, 59% and PCb, 55%).
Efficacy
Based on Kaplan-Meier estimates (Figure 2A), median
PFS in the ITT population was 4.44 months in the GEMOX
group versus 4.67 months in the PCb group. Rates of PFS
over time were also similar between the two treatment
groups: 0.67 and 0.66 at 3 months; 0.32 and 0.35 at 6 months;
and 0.10 and 0.09 at 12 months, for GEMOX and PCb,
respectively.
Clinical benefit, defined as a CR or PR or stable
disease (SD), was recorded in 53.4% of patients in the
GEMOX group (CR  0.5%, PR  14.7%, and SD 
38.2%) compared with 56.3% of patients in the PCb group
(CR  0%, PR  22.4%, and SD  33.9%). Median TTF
was 2.91 months in both the GEMOX and PCb groups,
with similar rates of TTF in both groups (0.50 and 0.49 at
3 months; and 0.11 and 0.14 at 6 months, for GEMOX and
PCb, respectively).
Randomized (n  =  383)
Received GEMOX (n  =  191) Received PCb (n  =  192)
Discontinuations (n  =  134)
   Deaths (n  =  10)
   Adverse events (n  =  62)
   Patient request (n  =  5)
   Investigator request (n = 1)
   Protocol deviation (n = 3)
   Disease progression (n = 48)
   Withdrew consent (n = 3)
   Failed entry (n = 1)*
   Other (n = 1)
Completed 6 cycles
of treatment
Discontinuations (n = 119)
   Deaths (n = 2)
   Adverse events (n = 53)
   Patient request (n = 5)
   Investigator request (n = 2)
   Disease progression (n = 50)
   Withdrew consent (n = 6)
   Failed entry (n = 1)*
GEMOX (n = 57) PCb (n = 73)
Two year follow-up
Discontinuations due to
normal completion (n = 37)
Discontinuations due to
normal completion (n = 60)
GEMOX (n = 20) PCb (n  =  13)
*Failed entry refers to patients who were randomized but withdrew consent before receiving study treatmentFIGURE 1. Patient disposition.
TABLE 1. Patient Demographics and Baseline
Characteristics (Intent-to-Treat Population)
GEMOX
(n  191)
PCb
(n  192)
Sex, n (%)
Male 104 (54.5) 108 (56.3)
Female 87 (45.5) 84 (43.8)
Median age (range), yr 63 (36–84) 64 (35–87)
Age 65 yr, n (%) 101 (52.9) 99 (51.6)
Race, n (%)
White 175 (91.6) 174 (90.6)
Nonwhite 16 (8.4) 18 (9.4)
ECOG performance status, n (%)
0 106 (55.5) 91 (47.4)
1 85 (44.5) 101 (52.6)
Stage IIIB disease, n (%) 30 (15.7) 30 (15.6)
Stage IV disease, n (%) 161 (84.3) 162 (84.4)
Histologic grade, n (%)
Squamous cell 40 (20.9) 38 (19.8)
Adenocarcinoma 113 (59.2) 106 (55.2)
Other 38 (19.9) 48 (25)
ECOG, Eastern Cooperative Oncology Group; GEMOX, gemcitabine plus oxali-
platin; PCb, paclitaxel plus carboplatin.
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There were 150 and 156 death events in the GEMOX
and PCb arms, respectively. Median OS was 9.90 (95%
confidence interval: 7.85–11.62; range: 0.07–31.42) months
in the GEMOX group and 9.24 (95% confidence interval:
8.18–10.89; range: 0.10–29.50) months in the PCb group.
Survival rates at 12, 18, and 24 months were also similar
between the two groups (Figure 2B).
After six cycles of treatment, the mean change in
QoL from baseline, as measured by TOI of the Functional
Assessment of Cancer Therapy-Lung scale, was 4.7 in
the GEMOX arm and 6.4 in the PCb arm. Nevertheless,
these results were affected by the decreasing numbers of
patients at each cycle and by the numbers of patients
failing to complete the questionnaire.
Results of the post hoc subgroup analyses are presented
in Table 2. Median OS in patients aged 70 years or older was
9.35 months for the GEMOX group and 9.80 months for the
PCb group (Figure 3A); median PFS in this subgroup was
similar in the two groups. In patients younger than 70 years,
both median OS and median PFS were similar between the
two treatment groups. For patients with adenocarcinoma
histology, PFS was similar in the two treatment groups,
although OS favored the GEMOX group.
Toxicity
Approximately two thirds of patients discontinued
treatment during the treatment phase of the study (GEMOX,
70.2% and PCb, 62.0%). The primary reasons for treatment
discontinuation were AEs (GEMOX, 32.5% and PCb,
27.6%), followed by disease progression, and then death. A
summary of grade 3/4 toxicities is presented in Table 3.
Grade 3/4 neurologic AEs are presented in Table 4. The most
common grade 3/4 toxicities were hematologic in nature,
with thrombocytopenia, neutropenia, and leukopenia being
the most prevalent in both groups (GEMOX: 30.4%, 25.0%,
and 4.9%, respectively; PCb: 5.9%, 41.7%, and 11.8%, re-
spectively). Fatigue (18.5% and 12.8% for GEMOX and PCb,
respectively) and dyspnea (13.6% and 8.6%, respectively)
were the most common nonhematologic grade 3/4 toxicities.
Grade 3/4 peripheral sensory neuropathy occurred at a higher
rate in the PCb group than in the GEMOX group (12.3%
versus 0.5%).
There were 144 deaths in the GEMOX arm and 153
deaths in the PCb arm. The main causes of death were PD
(GEMOX, 66.8% and PCb, 75.9%) and AEs (GEMOX,
12.5% and PCb, 6.4%). In the GEMOX group, the AEs listed
as leading to death included cardiac arrest, coma, congestive
heart failure, chronic obstructive pulmonary disease, coro-
nary artery disease, dyspnea, epistaxis/hemoptysis, hypersen-
sitivity to chemotherapy/pneumonitis, PD (seven patients),
pericarditis, pneumonia (three patients), respiratory distress,
sepsis, and thrombocytopenic purpura. AEs listed as leading
to death in the PCb group were allergic pneumonitis, cardio-
pulmonary arrest, neutropenic sepsis (two patients), PD,
pneumonia (two patients), and pulmonary embolism/deep
vein thrombosis. Six AEs leading to death in the GEMOX
group (two cases of PD and one case each of cardiac arrest,
congestive heart failure, hypersensitivity to chemotherapy/
pneumonitis, and thrombocytopenic purpura) and three
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FIGURE 2. A, Kaplan-Meier estimates of progression-free survival* (intent-to-treat population). B, Kaplan-Meier estimates of
overall survival (intent-to-treat population). GEMOX, gemcitabine plus oxaliplatin; PCb, paclitaxel plus carboplatin.
TABLE 2. Survival Times According to Patient Age and
Tumor Histology (Intent-to-Treat Population)
GEMOX PCb
Median OS, mo
Age 70 yra 10.10 8.71
Age 70 yrb 9.35 9.80
Adenocarcinoma histologyc 10.33 8.62
Median PFS, mo
Age 70 yra 4.37 4.34
Age 70 yrb 5.07 5.60
Adenocarcinoma histologyc 5.20 5.50
a GEMOX, n  145; PCb, n  132.
b GEMOX, n  46; PCb, n  60.
c GEMOX, n  113; PCb, n  106.
GEMOX, gemcitabine plus oxaliplatin; OS, overall survival; PCb, paclitaxel plus
carboplatin; PFS, progression-free survival.
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deaths in the PCb group (1.6%; two cases of neutropenic
sepsis and one case of allergic pneumonitis) were considered
by the investigators to be related to study treatment.
DISCUSSION
The objective of this study was to compare the efficacy
and tolerability of GEMOX with that of the current standard
of care, PCb, in chemotherapy-naive patients with advanced
NSCLC. No differences were observed between the two arms
of the study in terms of efficacy. Nevertheless, because of the
early closure of the study and the lack of sufficient statistical
power to conduct formal statistical comparisons, definitive
conclusions cannot be drawn.
The efficacy results observed with GEMOX are compa-
rable with those previously reported using various GEMOX
regimens in first-line NSCLC. Although the rates of objective
response (CR  PR) and clinical benefit (CR  PR  SD) in
this study were somewhat lower than in other studies, the
observed durations of PFS and OS were comparable. Median
PFS was 4.4 months compared with 2.7 to 7.3 months in
other studies, whereas median OS was 9.9 months compared
with 7.3 to 11.3 months in previous studies.8,11–13
Although this study was terminated early due to the
number of patients with AEs exceeding the prespecified
threshold for acceptable tolerability of either drug, the safety
results indicate that the toxicity of GEMOX is comparable
with that of PCb. The tolerability of GEMOX was also in line
with that observed in previous studies in NSCLC, where
hematologic AEs (mainly thrombocytopenia, neutropenia,
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TABLE 3. Grade 3/4 Adverse Events Reported by 5% of
Patients in Either Treatment Group (Safety Population)
Adverse Eventa
No. of Patients (%)
pb
GEMOX
(n  184)
PCb
(n  187)
Total grade 3/4 events 162 (88.0) 163 (87.2) 0.875
Nonhematologicc
Fatigue 34 (18.5) 24 (12.8) 0.154
Dyspnea 25 (13.6) 16 (8.6) 0.138
Platelet count decreased 22 (12.0) 5 (2.7) 0.0001
Nausea 15 (8.2) 11 (5.9) 0.422
Asthenia 12 (6.5) 13 (7.0) 1.000
Dehydration 11 (6.0) 14 (7.5) 0.680
Anorexia 10 (5.4) 8 (4.3) 0.637
Diarrhea 10 (5.4) 8 (4.3) 0.637
Hyponatremia 10 (5.4) 8 (4.3) 0.637
Neutrophil count decreased 8 (4.3) 14 (7.5) 0.272
Hyperglycemia 3 (1.6) 13 (7.0) 0.019
Arthralgia 2 (1.1) 13 (7.0) 0.006
Hematologicc
Thrombocytopenia 56 (30.4) 11 (5.9) 0.001
Neutropenia 46 (25.0) 78 (41.7) 0.001
Febrile neutropenia 1 (0.5) 8 (4.3)
Leukopenia 9 (4.9) 22 (11.8) 0.023
a Medical Dictionary for Regulatory Activities (version 9.0) preferred term.
b Fisher’s exact test.
c Listed in order of decreasing frequency in the GEMOX group.
GEMOX, gemcitabine plus oxaliplatin; PCb, paclitaxel plus carboplatin.
TABLE 4. Grade 3 or 4 Nervous System Disorders Reported
by 2% of Patients in Either Treatment Group
(Safety Population)
Adverse Eventa,b
No. of Patients (%)
pc
GEMOX
(n  184)
PCb
(n  187)
All grade 3/4 nervous system
disorders
13 (7.1) 52 (27.8) 0.001
Peripheral sensory neuropathy 1 (0.5) 23 (12.3) 0.001
Peripheral neuropathy 1 (0.5) 14 (7.5) 0.001
Peripheral motor neuropathy 1 (0.5) 5 (2.7) 0.215
Paraesthesia 0 5 (2.7) 0.061
Syncope 1 (0.5) 4 (2.1) 0.372
a Medical Dictionary for Regulatory Activities (version 9.0) preferred term.
b Listed in order of decreasing frequency in the PCb group.
c Fisher’s exact test.
GEMOX, gemcitabine plus oxaliplatin; PCb, paclitaxel plus carboplatin.
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and anemia) were the most common grade 3/4 toxici-
ties.8,11–17 As observed in previous studies, in this study,
neurotoxicity was relatively infrequent in patients who re-
ceived GEMOX; peripheral neuropathy occurred in approx-
imately 20% of patients who received PCb but was infrequent
in the GEMOX group. It is acknowledged that the discontin-
uation rate in this study was higher than in many other
studies. This may have been due, at least in part, to the
stringent requirements for withdrawal in our study. For ex-
ample, only one dose reduction for hematologic toxicity was
permitted before patients had to be withdrawn from the study,
and any grade 4 nonhematologic toxicity required discontin-
uation from study treatment.
As the proportion of older adult patients in the popu-
lation increases, it is increasingly important to understand
how best to manage older adult patients with cancer, and
particularly their response to, and tolerability of treatment.
Older adult patients have commonly been excluded from
studies of advanced NSCLC due to the expectation that this
older patient population will experience increased toxicity of
platinum-based regimens. In recent years, retrospective anal-
yses comparing elderly patients (age 70 years) with
younger patients (age 70 years) have been conducted.4,18 A
post hoc analysis of patients in this study who were aged 70
years or older (approximately 25% of patients) indicated that
median OS was similar in the GEMOX and PCb groups. In
addition, median survival of patients aged 70 years or older in
both the GEMOX and PCb groups were similar to those of
patients younger than 70 years, confirming findings of other
studies showing efficacy of doublet chemotherapy in older
patients with NSCLC. Age-specific subgroup analysis of the
ECOG 1594 study that compared four chemotherapy regi-
mens for advanced NSCLC found that fit elderly (70–80
years) patients displayed similar overall RRs, PFS, and OS,
compared with younger patients. These patients did, how-
ever, experience a higher rate of treatment-related toxicity.18
In contrast, retrospective analysis of the Southwest Oncology
Group 9509 and Southwest Oncology Group 9308 studies
found a trend toward shorter survival in patients aged 70
years or older compared with patients younger than 70 years.
In these studies, grade 3 to grade 5 toxicities were similar
between the two age groups.4 Further trials designed to
separate age from other factors are warranted.
The results of a second post hoc analysis suggest that
patients with adenocarcinoma histology may have better OS
after treatment with GEMOX compared with PCb. Previous
studies have reported improved activity of platinum-based
therapies (pemetrexed–cisplatin19 and platinum-doublet plus
gefitinib20) in patients with adenocarcinoma compared with
those with squamous tumor histology. A separate study that
assessed the efficacy and safety of cetuximab in combination
with cisplatin–vinorelbine compared with cisplatin–vinorel-
bine alone in NSCLC21 demonstrated a survival benefit of
cetuximab in combination with platinum-based chemother-
apy in advanced first-line NSCLC, irrespective of histology.21
Scagliotti et al.22 compared the combination of gemcitabine
plus cisplatin with pemetrexate plus cisplatin in 1725 patients
with advanced NSCLC and found a significant improvement
in survival in the cisplatinum–pemetrexate arm (12.6 versus
10.9 months, HR: 0.84) in those patients with adenocarci-
noma, as opposed to an inferior survival in those patients with
squamous cell carcinoma (9.4 versus 10.8 months, HR:
1.23).22 Recent studies have shown that expression levels of
ribonucleotide reductase subunit M1 correlate highly with the
efficacy of gemcitibine.23,24 Increased levels of the excision
and repair cross-complementation group 1 protein have been
found to indicate relative resistance to cisplatinum and car-
boplatinum but not to oxaliplatin.24,25 Furthermore, higher
levels of thymidylate synthetase have been observed in squa-
mous cell carcinomas, and this has an inverse effect on tumor
cell sensitivity to pemetrexate and oxaliplatin.25,26 Therefore,
different levels of ribonucleotide reductase subunit M1, ex-
cision and repair cross-complementation group 1, and thymi-
dylate synthetase in tumors could explain the different out-
comes according to tumor histology.
Scagliotti et al.27 conducted a small phase II trial
comparing pemetrexed combined with either oxaliplatin or
carboplatin in 80 patients with advanced NSCLC. Results
showed an RR of 26.8% for pemetrexed–oxaliplatin and
31.6% for pemetrexed–carboplatin, with an OS of 10.5
months in both groups. No information on tumor histology
was provided.27
The early closure of this study (because of the higher
than expected levels of toxicity) should discourage the initi-
ation of further trials in patients with squamous cell lung
cancer. Nevertheless, further prospective studies evaluating
the efficacy of oxaliplatin combinations in conjunction with
molecular and genomic tumor analysis may be warranted.
Although the results of this study suggest that patients
with adenocarcinoma histology may have better OS after
treatment with GEMOX compared with PCb, no improve-
ments in PFS were observed in this patient population after
treatment with GEMOX compared with PCb. It is, therefore,
likely that the improvement in OS seen in this patient popu-
lation may not be related to the initial chemotherapy program
and that second- and third-line treatments may be playing a
role in this survival outcome.
In conclusion, within the limitations of the premature
termination of this study, the results presented in this study
suggest similar efficacy and tolerability between GEMOX
and PCb when used as first-line therapy in the treatment of
patients with stage IIIb/IV NSCLC. The considerable tolera-
bility burden associated with both treatment regimens high-
lights the urgent need for improved treatment options and
identification of patients most likely to benefit from treatment
in terms of PFS and OS. In view of the relative increased
toxicity and AEs that occurred in this study, the combination
of gemcitabine and oxaliplatin at these doses and schedule
cannot be recommended as standard therapy for patients with
NSCLC.
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